Is This Biopharma Company With A Unique Business A Buy?
With a portfolio currently comprised of 45 commercial products and five developmental-stage candidates in various areas, including rare disease and neurology, the company featured in…
davidgoldstein
Profit From The “Urge To Merge” In The Diagnostics Space
On the heels of the news of Roche acquiring GenMark Diagnostics, the author of today’s article shares two more leading diagnostics companies that he believes are prime…
5 Stocks Under $10 Offering Solid Alpha Potential For Aggressive Investors
“These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” says the author of today’s…
“Not All Growth Is Created Equal”: 4 Strong Growth Tech And Biotech Stocks For Aggressive Investors
“With a huge tailwind from the massive stimulus program and the reopening of the economy as spring begins, now is the time to move from…
5 Stocks Under $10 With Solid Alpha Potential For Aggressive Traders
“With the number of new equity traders skyrocketing over the past year due to the Reddit/WallStreetBets popularity, locating good ideas to trade has become even…
As Small-Cap Stocks Outperform, Here Are 14 That Are Undervalued
“After lagging the broad market rebound in 2020, smaller companies staged a comeback in the latter part of that year and have been on a…
5 Biotech Stocks To Watch As The Industry Continues To Expand
“The biotech industry seems poised to continue its good run on the back of continued advancements in the field of research and subsequent speeding up…
3 Small-Cap Stocks With Big Potential
“While one could argue that small cap stocks are a bit riskier than large, well-funded behemoths, they’re also the place to look for the next…
Will Biotech Buck The Historical Trend This March? (And Where Will Biotech Go After 2021?)
Historically, January and February tend to be very strong months for biotech, while March tends to be very weak. But, with COVID-19 continuing to bear…
Balance Promising Growth And Interest Rate Risk With These 30 Stocks
As the economic recovery continues, Goldman Sachs is advising investors to “balance the appeal of promising businesses with the risk that [interest] rates rise further…